 BOSTON, Aug. 23, 2021 PRNewswire -- Stealth BioTherapeutics Corp Nasdaq: MITO, a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the United States Patent and Trademark Office has issued patents for Stealths lead product candidate, elamipretide, in the U.S. covering the treatment of Barth syndrome and Barth syndrome-related cardiomyopathy until February 2034. U.S. Patent Numbers 11,083,771 and 11,083,772, were granted on August 10, 2021, and include claims for the administration of elamipretide for treating Barth syndrome and Barth syndrome-related cardiomyopathy, respectively. 